Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Similar documents
Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

TB 101 Disease, Clinical Assessment and Lab Testing

Diagnosis of drug resistant TB

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

Treatment of Active Tuberculosis

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service

Ken Jost, BA, has the following disclosures to make:

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China

DRUG RESISTANCE IN TUBERCULOSIS

Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal

Molecular Methods in the Diagnosis of Drug Resistant Tuberculosis. Dr Sahajal Dhooria

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

Laboratory Diagnosis for MDR TB

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

The Molecular Epidemiology of Tuberculosis

DNA FINGERPRINTING. Barry N. Kreiswirth, PhD Director, PHRI TB Center

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Received 4 June 2013; Final revision 1 August 2013; Accepted 30 August 2013; first published online 27 September 2013

Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex. Objectives

Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose

Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008

Supplementary Appendix

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

Patterns of rpoc Mutations in Drug-Resistant Mycobacterium tuberculosis Isolated from Patients in South Korea

Optimising patient care in MDR TB with existing molecular screening tests in high burden countries

TB Laboratory for Nurses

Shah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Pyrosequencing Experience from Mumbai, India. Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

WSLH Testing and Surveillance Updates

Transmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University

DNA sequencing for the confirmation of rifampin resistance detected by Cepheid Xpert

DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?

MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex

Research in Tuberculosis: Translation into Practice

Diagnosis and Management of Active Tuberculosis

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

MSF Field Research. Diagnosis and management of drug-resistant tuberculosis. South African adults. Hughes, J; Osman, M

WELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears

When good genes go bad

White Paper Application

The Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida

Case presentation. Dr Connie Haley, MD, MPH Dr Gautam Kalyatanda, MD

Marcos Burgos, MD has the following disclosures to make:

Diagnosis and Treatment of Tuberculosis, 2011

Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis

Pharmacokinetics and doses of antituberculosis drugs in children

Chemotherapy of tuberculosis in Hong Kong: a consensus statement

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

New frontiers: Innovation and Access

TB Intensive San Antonio, Texas November 11 14, 2014

Management of Drug-resistant Tuberculosis (DR-TB)

Tuberculosis Tools: A Clinical Update

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

The current state of knowledge: genotypic vs phenotypic drug-susceptibility testing (DST)

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

The ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory

Multidrug-resistant Tuberculosis - World, Europe, Switzerland

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

Assessing the programmatic management of drug-resistant TB

Multi Drug Resistant tuberculosis (MDR-TB)

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

TOG The Way Forward

GLI model TB diagnostic algorithms

Analysis. Answers. Action. Saturday Night Fever. Shaka Brown Capital Congress

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Laboratory s Role in the Battle Against Drug Resistant Tuberculosis

The Efficacy of Genotype MTBDRplus Assay in Rapid Detection of Rifampicin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates

Update on Management of

Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.

Comparison of the Xpert MTB/RIF Assay and Real-time PCR for the Detection of Mycobacterium tuberculosis

HHS Public Access Author manuscript Int J Tuberc Lung Dis. Author manuscript; available in PMC 2016 April 01.

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

Multi-drug Resistant Tuberculosis in Rajshahi District

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

Mycobacterial cell wall. Cell Cycle Lengths. Outline of Laboratory Methods. Laboratory Methods

Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis

Characteristics of Mycobacterium

A retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece

Evaluation of the MTBDRsl Test for Detection of Second-Line-Drug Resistance in Mycobacterium tuberculosis

Mycobacterium tuberculosis and Molecular Epidemiology: An Overview

Online Annexes (2-4)

Tuberculosis Reference Laboratory, NIDCH, Mahakhali, Dhaka.

Tuberculosis: update 2013

GLI model TB diagnostic algorithms

Transcription:

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong

Tuberculosis Re-emerging problem in industrialized countries Infections in immuno-compromised patients Multi-drug resistant strains (MDR-TB) Mycobacterium tuberculosis (Mtb) Obligate aerobic, acid fast bacilli (AFB) Spread from person to person by aerosols - droplets infections Pulmonary tuberculosis

Diagnosis of Pulmonary Tuberculosis Chest X-ray Direct smear for AFB in sputum Turn around time < 2hr Low sensitivity (<50%) Sputum culture for M. tuberculosis 1~4 wk (solid / liquid medium) 1~2 wk (identification) High sensitivity (gold standard)

Conventional Laboratory Diagnosis for Tuberculosis

Molecular Diagnosis of Tuberculosis

Roche COBAS Taqman Abbott m2000tb

Chest X-ray Sputum Direct smear < 2 hr Sensitivity <50% 6-8 week Report Culture positive for MTB Gold Standard

Chest X-ray Sputum Direct smear < 2 hr Sensitivity <50% Sensitivity 85% - 93% Specificity 98% - 100% PCR for MTB 24 hr 6-8 week EJCMI D 2015 DMID 2012 Int J Antimicro Ag 2010 DMID 2004 J Clin Micro 2004 J Clin Micro 1997 Report Culture positive for MTB Gold Standard

Clinical Impact Polymerase Chain Reaction (PCR) for Mycobacterium tuberculosis is a rapid and reliable method in the diagnosis of tuberculosis, which allows early initiation of anti-tuberculosis therapy and management of patients. J Clin Pathol. 2004

Sample 1 ( sputum ): Reporting format M tuberculosis DNA detected (not detected) by PCR Not for monitoring treatment progress Sample 2 ( body fluids, tissues & wound swabs ): Result indeterminate due to presence of PCR inhibitors Sample 3 ( histological sections ): M tuberculosis DNA is often truncated due to formalin fixation, leading to false negative PCR result

Multidrug Therapy for Tuberculosis 3-9 months treatment of 2-3 primary drugs: Rifampin Isoniazid Streptomycin Ethambutol Pyrazinamide Fluoroquinolone

Cepheid s GeneXpert System Rapid Diagnosis of: 1) M. tuberculosis 2) Resistance to Rifampicin 3) $$$

Hain System (PCR-Reverse hybridization)

Rif R INH R

OFX R EMB R

Rifampin an effective anti-tuberculosis agent a surrogate marker of Multidrug-resistant tuberculosis (MDR-TB) rapid detection is important for the treatment and control of tuberculosis Resistance caused by the mutation in rpob gene

RNA Polymerase Subunit Gene 157bp (hot point mutations region) 526 516 531

Extensively Drug Resistant Tuberculosis ( XDR-TB ) Definition by WHO (October 2006): Resistance to at least isoniazid and rifampin among first-line anti-tb drugs Resistance to any fluoroquinolone, and resistance to at least one second-line injectable drug (amikacin, capreomycin, or kanamycin) High mortality rate (USA) Highly associated with HIV+ patients (USA)

Fluoroquinolones resistance in MTB DNA gyrase (Quinolone resistance-determining region - QRDR) - Ofloxacin Most gyrase A missense mutations were found at positions 90, 91, and 94 that were located within QRDR. Significant increase in MIC (>4.8µg/ml).

Direct detection of XDR-TB from Sputum [culture confirmation : INH R ; Rif R ; OFX R ]

Direct detection of XDR-TB from Sputum [culture confirmation : INH R ; Rif R ; OFX R ] S R S R

Sputum Direct smear < 1 hr Sensitivity <50% 6-8 week Report Culture positive for MTB with susceptibility test result 2 week Gold Standard

Sputum Direct smear < 2 hr katg MAS-PCR rpob PCR sequencing gyra PCR sequencing ~ 5 days J Antimicrob Chemother 2011 66(4) Diagn Microbial Infect Dis 2011 69(1) Antimicrob Agents Chemother 2011 55(2) Int J Antimicrob Agents 2010 35(2) Sensitivity <50% 6-8 week Report Culture positive for MTB with susceptibility test result 2 week Gold Standard

Known mutations associated with Rifampin and Ofloxacin resistance Rifampacin rpob (hot point mutations) 516 526 531 Fluoroquinolones gyra (hot point mutations) 90 91 94

Novel mutations associated with Rifampin and Ofloxacin resistance Rifampin MIC = 16-64 ug/ml rpob (hot point mutations) V146F I572F J Antimicrob Chemother 2011 66(4) Ofloxacin MIC = 8 ug/ml gyra (hot point mutations) A74S Antimicrob Agents Chemother 2011 55(2) Clone the mutated rpob gene into polyg and transformed in M. tuberculosis H37Ra.

Susceptible?: Reporting format Known mutation associated with resistance to Isoniazid/Rifampin/ Fluoroquinolones NOT detected Resistance : Mutation in katg gene associated with resistance to Isoniazid detected at S315T Mutation in rpob gene associated with resistance to Rifampin detected at S531L Mutation in gyra gene associated with resistance to Fluoroquinolones detected at A94G

Rapid Diagnosis of Tuberculosis Cepheid (TB + Rif ) 3 hours $$$$ Hain (TB + Rif+INH+OFX+AMI+EMB ) 1 day $$$$$ HKU /QMH ( in-house protocol ) TB qpcr qpcr + (~15%) DNA sequencing (Rif+INH+OFX ) 1 day ~3-5 days $

Summary PCR provides rapid diagnosis of M. tuberculosis - Early initiation of anti-tb therapy - Effective public health control MAS-PCR, PCR-sequencing provide rapid diagnosis of Rifampin, Ofloxacin and Isoniazid resistant M. tuberculosis (MDR-TB) Molecular diagnosis cannot replace conventional TB Laboratory practice Massive parallel sequencing or next-generation sequencing (NGS) to improve sensitivity

Acknowledgement HKU / QMH: Dr Gilman Siu Ricky Lau Prof KY Yuen Dr PL Ho Dr Vincent Cheng WT Hui Grace Kwan KW Leung Winnie Chan Barry Wong Simon Tong Hilda Leong Jonathan Ip Graham Hospital : Dr WW Yew Dr CF Wong TB & Chest Service : Dr CM Tam Dr CC Leung Dr KC Chang Johns Hopkins University: Prof Y Zhang